This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Hypertension
and you are
between 40 and 60
years old
-
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

Finding early predictors of myocardial in patients with hypertension 1. Scientific objective The study objective is to clarify the grounds of heart exertional dyspnoea stenocardial pain in patients with well-controlled stage I or II hypertension according to ESH (European Society of Hypertension), without changes in epicardial coronary arteries in coronary angiography and normal resting echocardiography result, and to assess of potential early markers of heart hypertrophy and failure in patients with hypertension. Characteristics of the final result The study is to allow for identification of patients with hypertension, in whom an early introduction of pharmacological treatment of heart failure should be considered. Evaluation in the detection of asymptomatic myocardial dysfunction will include potential heart failure markers such as: cardiotrophin 1, cystatin C, serum syndecan-4, collagen III N-terminal propetide [PIIINP], MMP-2, MMP-7, MMP-8, MMP-9 and NT-proBNP, modern echocardiography methods and magnetic resonance imaging in order to increase the effectiveness of prevention, diagnosis and treatment optimalization. 2. Project significance Prognosis in heart failure is very serious. It is similar or worse than in advanced cancer. These data indicate an extreme importance of the optimal early causal treatment of hypertension and symptomatic treatment of heart failure early stage in order to prevent the development advanced form of the disease, which has bad prognosis. In clinical practice, patients with well-controlled hypertension often report exercise limitation, exertional dyspnea and/or stenocardial pain which is not reflected in a standard resting echocardiography (normal result), without coronary artery disease data in electrocardiographic stress test and without change in epicardial coronary vessels in coronary angiography. The study is designed to establish the panel of diagnostic tests in patients with hypertension and exertional dyspnoea only, which will allow for early detection of abnormalities (before symptoms occur) and the start of the optimal treatment for these patients. Unfortunately, still too small percentage of patients receives full pharmacotherapy, hence the authors of the latest guidelines of procedure in heart failure and hypertension put great emphasis on this aspect. Optimal management may prevent the progression of these patients in stage C heart failure, and thus bring tangible benefits not only the patients themselves but also, by reducing the number of costly hospitalizations, significantly reduce health care costs. The number of hospitalizations for heart failure in Poland is estimated at 100 000 per year, and hospitalization costs exceed 70% of the total costs associated with the treatment of heart failure. The issue of exertional dyspnoea and overt heart failure in patients with hypertension and normal results of resting echocardiography is a new problem, both in Poland and in the world. So far, there are no treatment recommendations for this group of patients. Material and study plan 120 persons (age 40-60 years old) will be included in the study, patients with stage I or II primary hypertension according to the European Society of Hypertension: Group A- 40 patients without symptoms of heart failure Group B- 40 patients with exertional dyspnoea Group C - 40 patients with overt heart failure In group B (patients with exertional dyspnea/stenocardia) we will include only patients who have undergone contrast coronary angiography without any identified changes in the epicardial coronary arteries, which will facilitate answering the presented purpose of research. Patients in groups A and B with normal resting echocardiography and treated with a maximum of 2 antihypertensive drugs (an ACE inhibitor or a sartan as therapy base), according to the following regimen: ACEI/ARB + diuretic ACEI/ARB + calcium channel antagonist Group C - treatment in accordance with the standards for heart failure. Each patient will be informed about the objectives of the study and give written consent to participate. After signing informed consent patients will have performed the following tests: - Interview and documentation analysis, - Physical examination, - Electrocardiogram, - 24-hour blood pressure monitoring (ABPM), - 24-hour EKG recording, - Echocardiography at rest and during submaxinal exercise on a bicycle ergometer, - Flow-mediated dilatation (FMD), - Cardiac magnetic resonance imaging, - Standard labolatory parameters, - Levels of markers: cystatin C, cardiotrophin-1, metaloproteinases: MMP-2, MMP-7, MMP-8, MMP-9, Procollagen III N-Terminal Propeptide (PIIINP), Syndecan 4 (SDC4) and NT-proBNP Each patient will be informed about the objectives of the study and give written consent to participate.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01455714. The sponsor of the trial is Medical Universtity of Lodz and it is looking for 120 volunteers for the current phase.
Official trial title:
Finding Early Predictors of Myocardial Dysfunction in Patients With Hypertension